NAG-1 concentration was lower in the plasma samples of patients with benign tumors, such as follicular adenoma and nodular hyperplasia than in those with malignant thyroid cancer, such as PTC, FVPTC, and FTC, but the difference was not statistically significant (Figure S1A). This evidence concerns the gene GDF15 and thyroid cancer, nonmedullary, 2.